Lancet Obesity Definition Differs From Other Diagnostic Criteria for Adults

Obesity diagnosis may be on the verge of a major reset, as a new diagnostic study examines whether body mass index alone is too blunt an instrument for identifying the disease. Published in JAMA Network Open, the study compares the diagnostic accuracy of the Lancet Diabetes and Endocrinology Commission on Obesity definition with several other commonly used approaches. Its central question is both technical and highly consequential: can clinicians distinguish excess body fat that threatens health from a numerical BMI category that may not accurately describe an individual’s biological condition?

For decades, obesity has been classified primarily through BMI, calculated by dividing body weight in kilograms by height in meters squared. Although the measure is inexpensive, fast and easy to apply across large populations, it does not directly measure adipose tissue. Two people with the same BMI may have very different proportions of fat, muscle and bone, while fat distribution—particularly the accumulation of visceral fat around internal organs—can vary substantially. These differences can influence insulin resistance, cardiovascular risk, inflammation and physical function, yet remain invisible in a BMI-only diagnosis.

The Lancet Commission’s framework reflects a growing effort to make obesity definitions more clinically meaningful. Rather than treating obesity exclusively as a size or weight category, the commission’s approach considers whether excess adiposity is affecting the body’s normal functioning. This distinction is important because excess fat can exist without immediate symptoms or measurable organ impairment, while in other individuals it may contribute to diabetes, breathing problems, joint limitations, cardiovascular disease or other complications. A definition that captures these biological consequences could change who is diagnosed, monitored or offered treatment.

The new investigation, led by Aayush Visaria, MD, MPH, of Rutgers Robert Wood Johnson Medical School, evaluates how the commission’s definition performs against alternative obesity definitions. In diagnostic research, accuracy is not simply a matter of counting how many people meet a threshold. Researchers may assess sensitivity, or how effectively a definition identifies people who truly have the condition, and specificity, or how well it excludes those who do not. They may also examine predictive values, agreement between classification systems and how results differ across demographic or clinical subgroups.

Those comparisons could expose the strengths and weaknesses of the tools currently used in medical practice and public health surveillance. A highly sensitive definition might identify more people at potential risk, but could also classify individuals as having disease when their health is not impaired. A highly specific definition may reduce unnecessary labeling, yet miss patients whose excess adiposity is already damaging organs or restricting daily activities. The balance between these errors is not merely statistical: it can affect access to medication, surgery, insurance coverage, counseling and preventive care.

The study arrives as new anti-obesity medications have transformed public discussion about diagnosis and treatment. Drugs such as glucagon-like peptide-1 receptor agonists and related therapies are increasingly prescribed according to BMI thresholds, associated medical conditions and treatment guidelines. If the definition of obesity changes, the population considered eligible for therapy could change as well. A more precise framework might direct treatment toward patients with measurable health consequences, while also encouraging earlier intervention for people whose excess adiposity has not yet produced obvious organ dysfunction.

A revised definition could also reshape how obesity is understood by the public. BMI categories have often been interpreted as direct judgments about an individual’s health, despite their limitations. By emphasizing adipose tissue, physiological effects and functional status, the commission’s approach may support a more nuanced model that separates body size from disease severity. At the same time, any diagnostic system must be practical. Advanced body-composition imaging, laboratory testing and detailed functional assessments may improve precision, but they can be expensive, time-consuming or unavailable in routine care.

That tension between biological accuracy and real-world usability is likely to be central to the study’s importance. A definition can be scientifically sophisticated yet difficult to implement in primary-care clinics, community health programs or low-resource settings. Conversely, a simple measure can be widely deployed but fail to capture important differences between patients. The study’s comparison of multiple definitions may help clarify whether the Lancet framework offers a workable improvement, or whether its advantages depend on data and clinical assessments that are not routinely collected.

The findings may ultimately influence researchers, physicians and policymakers who rely on obesity statistics to estimate disease burden and allocate resources. Changing the diagnostic threshold or criteria could alter reported prevalence even if no one’s underlying health changes, making comparisons with older studies more difficult. It could also affect clinical trial recruitment, health-system planning and public-health targets. For that reason, diagnostic definitions must be judged not only by how well they classify individuals, but also by whether they produce consistent, transparent and clinically useful information.

The study does not reduce the obesity debate to a single number. Instead, it addresses a deeper problem in modern medicine: how to define a complex, heterogeneous disease using measures that are both scientifically valid and practical at scale. As the field moves beyond BMI-centered classification, the most influential definition may be the one that best connects excess adiposity with actual health outcomes while avoiding unnecessary labeling. The comparison published in JAMA Network Open provides a timely test of whether the Lancet Commission’s framework can meet that challenge.

Web References: https://doi.org/10.1001/jamanetworkopen.2026.27738

References: Visaria A, et al. Diagnostic study published in JAMA Network Open. DOI: 10.1001/jamanetworkopen.2026.27738.